New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe! Rheum Manpower Needs - More Programs https://t.co/xGXVFMkNra https://t.co/hcRGVMFZPE

Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/PEPmzZPeFr https://t.co/sS7IiYW9PR

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%are asymptomatic - Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative - Untreated, 9% risk of cirrhosis https://t.co/2QL2mz7Zhk https://t.co/YQ7jG1WnAG

View our interactive case study from the #SLEEducatorsNetwork to discover how you can apply the concept of disease modification to your patients with lupus. #Sponsored by GSK USMA https://t.co/not76wZPnI https://t.co/Reot2JbWpF

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/11dneH04bv https://t.co/pp0ELe5mqV

NRMP Results for rheumatology 2022 : - Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied) - Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied) WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/sqcIXxWrxx https://t.co/9xeUQeAuDD

Remibrutinib in Sjogren's Syndrome Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/ZcKU7MgXlm https://t.co/P9JBlxcdcx

Steroid injections worsen knee arthritis Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease. https://t.co/pAeU3IzZfx https://t.co/rgJeHM5t62

Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance. https… https://t.co/r0AlTD45gG

ACR22: Polymyalgia Rheumatica in the Spotlight One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run. https://t.co/4BpvYlKijY https://t.co/fTYYdmcE9X

Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/z3RTFt1hPb https://t.co/7rGn41qeu9

The Great Debate: To Treat or Not to Treat Pre RA Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22. https://t.co/s8FQ2l7k6Z https://t.co/zICWqhTfGL